Rhythm Pharmaceuticals (RYTM) Total Non-Current Liabilities (2016 - 2025)
Rhythm Pharmaceuticals (RYTM) posted quarterly Total Non-Current Liabilities of $210.2 million for Q4 2025, down 7.71% year-over-year from $227.7 million in Q4 2024, and down 7.71% quarter-over-quarter from $227.7 million in Q4 2024.
Rhythm Pharmaceuticals (RYTM) Total Non-Current Liabilities (2016 - 2025) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has reported Total Non-Current Liabilities for 6 consecutive years, with $210.2 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Non-Current Liabilities fell 7.71% year-over-year to $210.2 million; the TTM figure through Dec 2025 stood at $210.2 million (down 7.71% YoY), while the FY2025 annual figure was $210.2 million, down 7.71% from the prior year.
- Total Non-Current Liabilities retreated to $210.2 million in Q4 2025 per RYTM's latest filing, from $227.7 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $227.7 million in Q4 2024 and bottomed at $80.5 million in Q2 2022.
- Historically, Total Non-Current Liabilities has averaged $149.2 million across 4 years, with a median of $155.5 million in 2023.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities surged 57.03% — and 2025, when it declined 7.71%.
- Rhythm Pharmaceuticals' Total Non-Current Liabilities stood at $116.9 million in 2022, then soared by 38.46% to $161.8 million in 2023, then soared by 40.71% to $227.7 million in 2024, then retreated by 7.71% to $210.2 million in 2025.
- Business Quant data shows RYTM's Total Non-Current Liabilities at $210.2 million in Q4 2025, $227.7 million in Q4 2024, and $166.8 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Rhythm Pharmaceuticals | 7.95 Bn | 7.62 Bn | 62.32 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 210.17 Mn |
| Dec 31, 2024 | 227.72 Mn |
| Jun 30, 2024 | 166.76 Mn |
| Mar 31, 2024 | 162.47 Mn |
| Dec 31, 2023 | 161.84 Mn |
| Sep 30, 2023 | 155.54 Mn |
| Jun 30, 2023 | 126.34 Mn |
| Mar 31, 2023 | 125.91 Mn |
| Dec 31, 2022 | 116.88 Mn |
| Sep 30, 2022 | 107.50 Mn |
| Jun 30, 2022 | 80.46 Mn |
| Sep 30, 2017 | 5.38 Mn |
| Dec 31, 2016 | 5.04 Mn |